This news cracked me up so I thought of sharing...
"NuPathe Inc. is down 53% over 12 months. The current share price is $1.70, down 47% since Ronald Muhlenkamp made a new buy as of June 30, 2013.
He bought 11,000 shares at an average price of $3.22 for a loss of 48.1%.
His current shares are 11,000.
Incorporated in 2005, NuPathe Inc. is a biopharmaceutical company that develops and commercializes branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders.
The company has a market cap of $52.3 million; shares trade with a P/B ratio of 3.80.
Tracking historical share pricing, revenue and net income:
As of the second quarter of 2013, Ronald Muhlenkamp is one of two gurus holding PATH. There is no recent insider activity to report."